Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients

Objectives: This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in a cohort of cervical cancer (CC) patients evaluating its prognostic significance. Methods: All patients diagnosed at Brazilian National Cancer Institute (INCA),...

Full description

Saved in:
Bibliographic Details
Main Authors: Michelle Marques Lessa, Andreia C. Melo, Eduardo Paulino, Thais dos Santos Rocha Abreu, Carlos Gil Ferreira, Luiz Claudio Santos Thuler
Format: Article
Language:English
Published: Thieme Revinter Publicações Ltda. 2022-10-01
Series:Brazilian Journal of Oncology
Subjects:
Online Access:https://www.brazilianjournalofoncology.com.br/details/193/en-US/prevalence-and-prognostic-value-of-the-programmed-cell-death-ligand-1--pd-l1--expression-among-tumor-samples-from-cervical-cancer-patients
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850120275504398336
author Michelle Marques Lessa
Andreia C. Melo
Eduardo Paulino
Thais dos Santos Rocha Abreu
Carlos Gil Ferreira
Luiz Claudio Santos Thuler
author_facet Michelle Marques Lessa
Andreia C. Melo
Eduardo Paulino
Thais dos Santos Rocha Abreu
Carlos Gil Ferreira
Luiz Claudio Santos Thuler
author_sort Michelle Marques Lessa
collection DOAJ
description Objectives: This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in a cohort of cervical cancer (CC) patients evaluating its prognostic significance. Methods: All patients diagnosed at Brazilian National Cancer Institute (INCA), in 2011, with invasive CC, squamous cell carcinoma (SCC) or adenocarcinoma (ADC) were retrospectively included. Clinical and treatment data were collected and PD-L1 expression was evaluated according to the percentage of viable tumor cells showing staining. The survival analysis was performed using the Kaplan Meier method. Results: In total, 152 patients (105 SSC and 47 ADC) were included and the mean age was 52.4 years (±14.4). According to the International Federation of Gynecology and Obstetrics (FIGO) 2009, 84.2% had locally advanced disease (IB2-IVA). PD-L1 expression was considered positive (=1%) in 53.3% of the cases. After adjustment, the multivariable analysis confirmed that SCC (p=0.026) and tumor size >4cm (p=0.023) were independently associated with PD-L1 expression. There were no significant differences in disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) comparing the subgroups with distinct PD-L1 expression. Conclusion: In this cohort, PD-L1 expression was not associated with DFS, DSS and OS.
format Article
id doaj-art-6941135915d04d03bd4e4745c1f63548
institution OA Journals
issn 2526-8732
language English
publishDate 2022-10-01
publisher Thieme Revinter Publicações Ltda.
record_format Article
series Brazilian Journal of Oncology
spelling doaj-art-6941135915d04d03bd4e4745c1f635482025-08-20T02:35:24ZengThieme Revinter Publicações Ltda.Brazilian Journal of Oncology2526-87322022-10-01180010.5935/2526-8732.20220313Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patientsMichelle Marques Lessa0Andreia C. Melo1Eduardo Paulino2Thais dos Santos Rocha Abreu3Carlos Gil Ferreira4Luiz Claudio Santos Thuler5https://orcid.org/0000-0003-2550-6537Brazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development - Rio de Janeiro - Rio de Janeiro - BrazilBrazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development - Rio de Janeiro - Rio de Janeiro - BrazilBrazilian National Cancer Institute (INCA), Section of Clinical Oncology - Rio de Janeiro - Rio de Janeiro - BrazilBrazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development - Rio de Janeiro - Rio de Janeiro - BrazilOncoclínicas, Clinical Oncology - Sao Paulo - Sao Paulo - BrazilBrazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development - Rio de Janeiro - Rio de Janeiro - BrazilObjectives: This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in a cohort of cervical cancer (CC) patients evaluating its prognostic significance. Methods: All patients diagnosed at Brazilian National Cancer Institute (INCA), in 2011, with invasive CC, squamous cell carcinoma (SCC) or adenocarcinoma (ADC) were retrospectively included. Clinical and treatment data were collected and PD-L1 expression was evaluated according to the percentage of viable tumor cells showing staining. The survival analysis was performed using the Kaplan Meier method. Results: In total, 152 patients (105 SSC and 47 ADC) were included and the mean age was 52.4 years (±14.4). According to the International Federation of Gynecology and Obstetrics (FIGO) 2009, 84.2% had locally advanced disease (IB2-IVA). PD-L1 expression was considered positive (=1%) in 53.3% of the cases. After adjustment, the multivariable analysis confirmed that SCC (p=0.026) and tumor size >4cm (p=0.023) were independently associated with PD-L1 expression. There were no significant differences in disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) comparing the subgroups with distinct PD-L1 expression. Conclusion: In this cohort, PD-L1 expression was not associated with DFS, DSS and OS.https://www.brazilianjournalofoncology.com.br/details/193/en-US/prevalence-and-prognostic-value-of-the-programmed-cell-death-ligand-1--pd-l1--expression-among-tumor-samples-from-cervical-cancer-patientsimmune checkpoint inhibitorsuterine cervical neoplasmssurvival
spellingShingle Michelle Marques Lessa
Andreia C. Melo
Eduardo Paulino
Thais dos Santos Rocha Abreu
Carlos Gil Ferreira
Luiz Claudio Santos Thuler
Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients
Brazilian Journal of Oncology
immune checkpoint inhibitors
uterine cervical neoplasms
survival
title Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients
title_full Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients
title_fullStr Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients
title_full_unstemmed Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients
title_short Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients
title_sort prevalence and prognostic value of the programmed cell death ligand 1 pd l1 expression among tumor samples from cervical cancer patients
topic immune checkpoint inhibitors
uterine cervical neoplasms
survival
url https://www.brazilianjournalofoncology.com.br/details/193/en-US/prevalence-and-prognostic-value-of-the-programmed-cell-death-ligand-1--pd-l1--expression-among-tumor-samples-from-cervical-cancer-patients
work_keys_str_mv AT michellemarqueslessa prevalenceandprognosticvalueoftheprogrammedcelldeathligand1pdl1expressionamongtumorsamplesfromcervicalcancerpatients
AT andreiacmelo prevalenceandprognosticvalueoftheprogrammedcelldeathligand1pdl1expressionamongtumorsamplesfromcervicalcancerpatients
AT eduardopaulino prevalenceandprognosticvalueoftheprogrammedcelldeathligand1pdl1expressionamongtumorsamplesfromcervicalcancerpatients
AT thaisdossantosrochaabreu prevalenceandprognosticvalueoftheprogrammedcelldeathligand1pdl1expressionamongtumorsamplesfromcervicalcancerpatients
AT carlosgilferreira prevalenceandprognosticvalueoftheprogrammedcelldeathligand1pdl1expressionamongtumorsamplesfromcervicalcancerpatients
AT luizclaudiosantosthuler prevalenceandprognosticvalueoftheprogrammedcelldeathligand1pdl1expressionamongtumorsamplesfromcervicalcancerpatients